Tesamorelin and Sermorelin With GLP-1s: Do They Help With Weight Loss or Visceral Fat?

Joshua Silva, MD
Jul 4
5 min read

Quick answer: No, tesamorelin and sermorelin are not proven add-ons to GLP-1 medications for weight loss. Tesamorelin has evidence for reducing deeper abdominal fat, called visceral fat, in adults with HIV-associated lipodystrophy, but it is not FDA-approved for general weight loss. Sermorelin is sometimes marketed for weight loss, but strong clinical studies have not shown that it improves weight loss, visceral fat loss,

or muscle preservation when combined with semaglutide or tirzepatide.^1-7

Can Tesamorelin Be Used With Semaglutide or Tirzepatide for Weight Loss?

Not as an evidence-based weight-loss add-on. Tesamorelin has not been well studied with semaglutide, tirzepatide, or other GLP-1 medications for weight loss. At this time, there is no good clinical evidence showing that adding tesamorelin to a GLP-1 medication leads to greater weight loss or meaningful additional visceral fat reduction.

That does not prove the combination has no effect. It means the combination is not currently evidence-based for routine weight loss treatment.

Does Tesamorelin Cause Weight Loss?

No, tesamorelin is not considered a general weight-loss medication. Tesamorelin can reduce visceral abdominal fat in adults with HIV-associated lipodystrophy, but it usually does not cause major weight loss on the scale. The FDA-approved labeling states that tesamorelin is not indicated for weight-loss management.¹

This distinction matters. A medication may reduce deeper abdominal fat without causing a large change in total body weight.

Does Tesamorelin Reduce Visceral Fat?

Yes, tesamorelin can reduce visceral fat in certain patients. Clinical trials show that tesamorelin can reduce visceral adipose tissue, especially in adults with HIV-associated lipodystrophy.2^,3 Visceral fat is the deeper abdominal fat stored around internal organs.

However, this evidence mainly applies to a specific medical condition. It does not prove that tesamorelin should be used for routine obesity treatment, cosmetic abdominal fat loss, or as a standard add-on to GLP-1 medications.

Has Tesamorelin Been Studied for Obesity Without HIV?

Yes, but only in limited non-HIV populations. In one randomized trial, researchers studied abdominally obese adults with reduced growth hormone secretion. In that specific group, tesamorelin reduced CT-measured visceral fat and improved some metabolic markers.⁴

This study is interesting, but it was not a broad obesity trial. Results from adults with reduced growth hormone secretion may not apply to most patients with typical obesity, insulin resistance, or patients already using GLP-1 medications.

Does Tesamorelin Work for Weight Loss in Type 2 Diabetes?

No clear weight-loss benefit was shown in type 2 diabetes. In a 12-week study of adults with type 2 diabetes, tesamorelin did not significantly improve weight, BMI, body fat percentage, or waist circumference.⁵This study does not support tesamorelin as a reliable weight-loss treatment for patients with type 2 diabetes.

The study was relatively short, but the finding is important. Many patients interested in GLP-1 medications also have insulin resistance, prediabetes, or type 2 diabetes.

Is Sermorelin Effective for Weight Loss?

No, sermorelin is not an evidence-based weight-loss medication. Sermorelin signals the body to release more growth hormone, but that does not mean it reliably causes fat loss or weight loss.

Older studies of sermorelin or related growth-hormone–releasing hormone therapies showed changes in growth hormone and IGF-1 activity. However, those studies did not prove that sermorelin is an effective treatment for obesity, visceral fat reduction, or muscle preservation during GLP-1 treatment.^6,7

Can Sermorelin Be Used With Semaglutide or Tirzepatide?

Not as a proven weight-loss combination. Sermorelin has not been shown in good human clinical trials to improve weight loss, visceral fat loss, or muscle preservation when combined with semaglutide or tirzepatide.

Some clinics market sermorelin with GLP-1 medications for “body recomposition.” That may sound appealing, but those claims are mostly based on theory, not strong clinical outcome data.

Tesamorelin vs Sermorelin for Weight Loss: Which Has Better Evidence?

Tesamorelin has better evidence for visceral fat reduction, but neither is proven as a GLP-1 weight-loss add-on. esamorelin has clinical trial evidence in adults with HIV-associated lipodystrophy. Sermorelin has not been proven in strong clinical studies to produce meaningful weight loss or improve GLP-1 results.^1-7

In practical terms, tesamorelin is better supported for a specific medical use involving visceral fat. Sermorelin is mostly promoted based on its effect on the growth hormone pathway rather than strong evidence for obesity treatment.

Do GLP-1 Medications Already Reduce Visceral Fat?

Yes, GLP-1 medications can reduce visceral fat as part of overall weight loss. A systematic review and meta-analysis found that GLP-1 receptor agonists significantly reduced visceral fat and liver fat in adults.⁸ Semaglutide 2.4 mg body-composition analyses have also reported reductions in total fat mass and regional visceral fat mass.⁹

For most patients, optimizing GLP-1 treatment, nutrition, protein intake, resistance training, and long-term follow-up is more evidence-based than adding unproven peptide combinations.

Should Patients Take Tesamorelin or Sermorelin With GLP-1s?

Usually, no—not as a routine weight-loss strategy. Patients should not view tesamorelin or sermorelin as proven add-ons to GLP-1 medications for weight loss. Current evidence does not show that either peptide meaningfully improves semaglutide or tirzepatide results.

For patients using GLP-1 medications, the most evidence-based strategy remains individualized dosing, adequate protein intake, progressive resistance training, side-effect management, and avoiding unnecessarily rapid weight loss.

Key Takeaway

No, tesamorelin and sermorelin are not proven GLP-1 add-ons for weight loss. Tesamorelin may reduce visceral fat in specific medical populations, especially adults with HIV-associated lipodystrophy, but it is not FDA-approved for general weight loss. Sermorelin is sometimes marketed for weight loss, but strong clinical studies have not shown meaningful benefits for obesity, visceral fat reduction, or GLP-1-related muscle preservation.

References

1. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use [prescribing information]. Theratechnologies Inc; revised March 2025. Accessed June 8, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf

2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490 https://pubmed.ncbi.nlm.nih.gov/20101189/

3. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334 https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/

4. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. doi:10.1210/jc.2012-2794 https://academic.oup.com/jcem/article-abstract/97/12/4769/2536677?redirectedFrom=fulltext&login=false

5. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. 2017;12(6). doi:10.1371/journal.pone.0179538 https://pmc.ncbi.nlm.nih.gov/articles/PMC5472315/

6. Khorram O, Laughlin GA, Yen SSC. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. doi:10.1210/jcem.82.5.3943 https://academic.oup.com/jcem/article-abstract/82/5/1472/2823341

7. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/S0026-0495(97)90174-8 https://pubmed.ncbi.nlm.nih.gov/9005976/

8. Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis. PLoS One. 2023;18(8). doi:10.1371/journal.pone.0289616 https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0289616

9. Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(suppl 1). doi:10.1210/jendso/bvab048.030 https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/